IL307673A - Mek inhibitors and uses thereof - Google Patents

Mek inhibitors and uses thereof

Info

Publication number
IL307673A
IL307673A IL307673A IL30767323A IL307673A IL 307673 A IL307673 A IL 307673A IL 307673 A IL307673 A IL 307673A IL 30767323 A IL30767323 A IL 30767323A IL 307673 A IL307673 A IL 307673A
Authority
IL
Israel
Prior art keywords
mek inhibitors
mek
inhibitors
Prior art date
Application number
IL307673A
Other languages
Hebrew (he)
Inventor
Alfredo C Castro
Michael J Burke
John Proudfoot
Sabine K Ruppel
Thomas A Wynn
Original Assignee
Ikena Oncology Inc
Alfredo C Castro
Michael J Burke
John Proudfoot
Sabine K Ruppel
Thomas A Wynn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ikena Oncology Inc, Alfredo C Castro, Michael J Burke, John Proudfoot, Sabine K Ruppel, Thomas A Wynn filed Critical Ikena Oncology Inc
Publication of IL307673A publication Critical patent/IL307673A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL307673A 2021-04-16 2022-04-15 Mek inhibitors and uses thereof IL307673A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163175837P 2021-04-16 2021-04-16
US202163262093P 2021-10-05 2021-10-05
PCT/US2022/071732 WO2022221866A1 (en) 2021-04-16 2022-04-15 Mek inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
IL307673A true IL307673A (en) 2023-12-01

Family

ID=81579550

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307673A IL307673A (en) 2021-04-16 2022-04-15 Mek inhibitors and uses thereof

Country Status (7)

Country Link
EP (1) EP4323066A1 (en)
JP (1) JP2024514879A (en)
KR (1) KR20230172548A (en)
AU (1) AU2022258968A1 (en)
CA (1) CA3215081A1 (en)
IL (1) IL307673A (en)
WO (1) WO2022221866A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202404581A (en) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Mek inhibitors and uses thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (en) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Ring gap magnet system
EA006227B1 (en) 1999-12-10 2005-10-27 Пфайзер Продактс Инк. PIRROLO(2,3-d)PYRIMIDINE COMPOUNDS
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
DK1389617T3 (en) 2001-04-27 2007-05-07 Zenyaku Kogyo Kk Heterocyclic compound and anti-tumor agent containing it as the active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2495072A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
JP2006523237A (en) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド PI-3 kinase inhibitor prodrug
KR101168441B1 (en) 2003-05-30 2012-07-25 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
ES2397825T3 (en) * 2004-06-11 2013-03-11 Japan Tobacco, Inc. 5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido [2,3-d] pyrimidine derivatives and related compounds for cancer treatment
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
WO2007040650A2 (en) 2005-05-12 2007-04-12 Abbott Laboratories Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR101888321B1 (en) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
ES2513165T3 (en) 2005-10-07 2014-10-24 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol-3-kinase inhibitors
BR122021011787B1 (en) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Biaryl metapyrimidine kinase inhibitors, pharmaceutical composition and process for preparing a pharmaceutical composition
UA116187C2 (en) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн HETERO aryl substituted pyrrolo [2,3-b] Pyridines and pyrrolo [2,3-b] Pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
AR060631A1 (en) 2006-04-26 2008-07-02 Piramed Ltd DERIVATIVES OF PIRIMIDINE AND ITS USE AS INHIBITORS OF PHOSFATIDYLNOSITOL 3-QUINASE (PI3K)
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
KR20150043565A (en) 2007-03-12 2015-04-22 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 Phenyl amino pyrimidine compounds and uses thereof
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
JP5932217B2 (en) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Combination therapy using GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (en) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション IDO inhibitor
PT2288610T (en) 2008-03-11 2016-10-17 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
JP2011523616A (en) 2008-05-29 2011-08-18 サン−ゴバン サントル ドゥ ルシェルシェ エ デトゥードゥ ユーロペン Porous structure containing aluminum titanate
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
CN102245640B (en) 2008-12-09 2014-12-31 霍夫曼-拉罗奇有限公司 Anti-PD-L1 antibodies and their use to enhance T-cell function
SG178991A1 (en) 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
NZ599516A (en) 2009-12-10 2013-11-29 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
JP5989547B2 (en) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Antibody to human CSF-1R and use thereof
CN102918060B (en) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 Anti-human CSF-1R antibody and uses thereof
TR201900368T4 (en) 2010-05-04 2019-02-21 Five Prime Therapeutics Inc Antibodies that bind to Csf1r.
NZ714128A (en) 2010-09-09 2017-10-27 Pfizer 4-1bb binding molecules
KR102243575B1 (en) 2010-12-09 2021-04-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Use of chimeric antigen receptor-modified t cells to treat cancer
NO2694640T3 (en) 2011-04-15 2018-03-17
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
PT2785375T (en) 2011-11-28 2020-10-29 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
EP2812355A4 (en) 2012-02-06 2016-03-02 Hoffmann La Roche Compositions and methods for using csf1r inhibitors
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
KR20140138910A (en) * 2012-03-14 2014-12-04 루핀 리미티드 Heterocyclyl compounds
RU2670743C9 (en) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP2986611B1 (en) * 2013-04-18 2019-02-06 Shanghai Fochon Pharmaceutical Co. Ltd Certain protein kinase inhibitors
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
EP3353156B1 (en) 2015-09-23 2021-11-03 The General Hospital Corporation Tead transcription factor autopalmitoylation inhibitors
MY196809A (en) 2015-12-24 2023-05-03 Kyowa Kirin Co Ltd (),()-unsaturated amide compound
CA3062294A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
WO2018235926A1 (en) 2017-06-23 2018-12-27 協和発酵キリン株式会社 α, β-UNSATURATED AMIDE COMPOUND
MX2019015431A (en) * 2017-06-23 2021-03-30 Cstone Pharmaceuticals Coumarin-like cyclic compound as mek inhibitor and use thereof.
CA3073543A1 (en) 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. Benzosulfonyl compounds
US11524943B1 (en) 2017-12-06 2022-12-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
US11247082B2 (en) 2018-05-04 2022-02-15 ArchAngel Fire Systems Holdings, LLC System, method, and apparatus for the suppression of fire growth
WO2019222431A1 (en) 2018-05-16 2019-11-21 Vivace Therapeutics, Inc. Oxadiazole compounds
CN112204029B (en) 2018-05-31 2024-03-01 豪夫迈·罗氏有限公司 Therapeutic compounds
JP7535500B2 (en) 2018-09-03 2024-08-16 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Carboxamide and Sulfonamide Derivatives Useful as TEAD Modulators
EP3866798A4 (en) 2018-10-15 2022-07-13 Dana-Farber Cancer Institute, Inc. Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof
MX2021005314A (en) 2018-11-09 2021-08-24 Vivace Therapeutics Inc Bicyclic compounds.
AU2020241258A1 (en) 2019-03-15 2021-10-07 The General Hospital Corporation Novel small molecule inhibitors of tead transcription factors
EP3956033A4 (en) 2019-04-16 2023-01-11 Vivace Therapeutics, Inc. Bicyclic compounds
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN114466839A (en) 2019-05-31 2022-05-10 医肯纳肿瘤学公司 TEAD inhibitors and uses thereof
EP4087868A4 (en) 2020-01-08 2024-03-20 Icahn School of Medicine at Mount Sinai Small molecule modulators ksr-bound mek
WO2022051569A1 (en) 2020-09-04 2022-03-10 Ikena Oncology, Inc. Substituted 3-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions
WO2022051567A1 (en) 2020-09-04 2022-03-10 Ikena Oncology, Inc. Substituted pyrido[2,3-b]pyrazinones and reuated compounds and their use in treating medicau conditions
WO2022051565A1 (en) 2020-09-04 2022-03-10 Ikena Oncology, Inc. Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions
WO2022051568A1 (en) 2020-09-04 2022-03-10 Ikena Oncology, Inc. Substituted 4-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions

Also Published As

Publication number Publication date
WO2022221866A1 (en) 2022-10-20
AU2022258968A1 (en) 2023-10-19
EP4323066A1 (en) 2024-02-21
JP2024514879A (en) 2024-04-03
CA3215081A1 (en) 2022-10-20
KR20230172548A (en) 2023-12-22

Similar Documents

Publication Publication Date Title
EP4232425A4 (en) Ctps1 inhibitors and uses thereof
IL288381A (en) Tead inhibitors and uses thereof
IL288384A (en) Tead inhibitors and uses thereof
EP4087840A4 (en) Mek inhibitors and therapeutic uses thereof
EP4138875A4 (en) Ras inhibitors and uses thereof
IL289612A (en) Hpk1 inhibitors and uses thereof
IL282090A (en) Tyk2 inhibitors and uses thereof
IL284799A (en) Tyk2 inhibitors and uses thereof
IL307187A (en) Mk2 inhibitors and uses thereof
IL286248A (en) Tyk2 inhibitors and uses thereof
EP4185380A4 (en) Quinazolinone hsd17b13 inhibitors and uses thereof
EP4165049A4 (en) Isotryptamine psychoplastogens and uses thereof
IL291217A (en) Usp30 inhibitors and uses thereof
GB202006792D0 (en) Method and uses thereof
EP4161917A4 (en) Grk2 inhibitors and uses thereof
EP4192836A4 (en) Atr inhibitors and uses thereof
IL286622A (en) Prmt5 inhibitors and uses thereof
IL307165A (en) Alk-5 inhibitors and uses thereof
IL314009A (en) Parp1 inhibitors and uses thereof
EP4175948A4 (en) Atr inhibitors and uses thereof
IL307673A (en) Mek inhibitors and uses thereof
EP4017857A4 (en) Mettl16 inhibitors and uses thereof
EP3976009A4 (en) Bax inhibitors and uses thereof
IL311588A (en) Lpxc inhibitors and uses thereof
IL291895A (en) Mcl1 inhibitors and uses thereof